Flutemetamol (18F) Injection

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Mild Cognitive Impairment

Conditions

Mild Cognitive Impairment, Alzheimer's Disease

Trial Timeline

Dec 1, 2009 → Jan 1, 2014

NCT ID

NCT01028053

About Flutemetamol (18F) Injection

Flutemetamol (18F) Injection is a phase 3 stage product being developed by Medpace for Mild Cognitive Impairment. The current trial status is completed. This product is registered under clinical trial identifier NCT01028053. Target conditions include Mild Cognitive Impairment, Alzheimer's Disease.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01028053	Phase 3	Completed	Dec 1, 2009	Jan 1, 2014	Mild Cognitive Impairment

Competing Products

20 competing products in Mild Cognitive Impairment

See all competitors

Product	Company	Stage	Hype Score
Neurosteroid enantiomer	Oragenics	Phase 2	44
Ranirestat + Placebo	Eisai	Phase 2/3	65
Aricept (donepezil hydrochloride) + placebo	Eisai	Approved	85
Donepezil HCl	Eisai	Approved	85
Donanemab + Aducanumab	Eli Lilly	Phase 3	77
PPAR alpha + Hydrochlorothiazide + Placebo	Eli Lilly	Phase 2	52
Elagolix	AbbVie	Approved	85
AZD1446 + Placebo	AstraZeneca	Phase 2	52
MEDI1814 for IV injection + MEDI1814 for Subcutaneous Injection + IV Placebo + Placebo for Subcutaneous Injection	AstraZeneca	Phase 1	33
Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcg	AstraZeneca	Approved	85
AZD5213 + AZD5213 + AZD5213	AstraZeneca	Phase 2	52
budesonide/formoterol (Symbicort)	AstraZeneca	Phase 3	77
MK-8931	Merck	Phase 1	33
Montelukast to placebo + Placebo to montelukast	Merck	Pre-clinical	23
Verubecestat 12 mg (Parts 1 and 2) + Verubecestat 40 mg (Parts 1 and 2)	Merck	Phase 3	77
Aliskiren + Hydrochlorothiazide + Amlodipine	Novartis	Approved	85
LCZ696 + Sildenafil	Novartis	Phase 2	52
QCZ484 + Placebo	Novartis	Phase 1	33
Rivastigmine Patch	Novartis	Approved	85
AFQ056	Novartis	Phase 1	33

Other Products from Medpace

Lesinurad + XOI + Placebo + colchicine + corticosteroidsApproved

VI-0521 + VI-0521 + Placebo matched phentermine/topiramatePhase 3

TNX-103 + PlaceboPhase 3

lerodalcibepPhase 3